[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100366498":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":45,"collaborators":7,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":7,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":7,"briefSummary":62,"conditions":63,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Immunis.AI","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Subtraction Normalized Expression of Phagocytes Blood Test","Non-invasive blood based immunogenomic assay that targets RNA sequencing to identify disease and disease aggressiveness",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Jessica DeHart","CONTACT","619-316-1416","jessica.dehart@oncocellmdx.com",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Comprehensive Urology","RECRUITING","Royal Oak","Michigan","48197","United States","US",{"type":29,"coordinates":30},"Point",[31,32],-83.14465,42.48948,{"lat":32,"lon":31},[35,39,42],{"name":36,"role":16,"phone":37,"phoneExt":7,"email":38},"Bridget Makhlouf","248-336-1080","bmakhlouf@urologist.org",{"name":40,"role":16,"phone":37,"phoneExt":7,"email":41},"Patrick Keating","pkeating@urologist.org",{"name":43,"role":44,"phone":7,"phoneExt":7,"email":7},"Howard Korman, MD","PRINCIPAL_INVESTIGATOR",{"type":46,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100366498","active-surveillance-snep-assay-registry-trial-for-prostate-cancer-100366498",false,"NCT04052048","Active Surveillance SNEP Assay Registry Trial for Prostate Cancer","A Multi-center, Prospective Active Surveillance Registry Trial Assessing the Performance of a Non-invasive Immunogenomic Blood Test for Indolent Prostate Cancer Disease Management.","Inclusion Criteria\n\n* Men between 40-80 of age with at least a 10-year life expectancy\n* All active surveillance protocols are accepted\n* No PSA limits\n\nCategory 1:\n\n* Patient is currently on active surveillance with only ONE previous low grade prostate biopsy.\n* Patient must already be scheduled for their 1st annual biopsy under their active surveillance protocol within 90 days of enrollment date.\n\nCategory 2:\n\n• Patient is recently diagnosed with low grade prostate cancer but has decided against active surveillance and is scheduled for radical prostatectomy within 90 days of enrollment date.\n\nExclusion Criteria:\n\nMen on watchful waiting i.e. those with less than 10-year life expectancy with no intent for curative therapy\n\n* Men with symptoms or rising PSA who have not been proven to have cancer by tissue biopsy i.e. men with only negative prostate biopsies.\n* Patients with a history of a different cancer (except basal cell carcinoma)","MALE","40 Years","80 Years",{"count":58,"type":59},2000,"ESTIMATED","10 Years","OBSERVATIONAL","A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.",[64],"Prostate Cancer Aggressiveness","2026-03-29",{"date":67,"type":68},"2026-04-02","ACTUAL",{"date":70,"type":68},"2019-09-09",{"date":72,"type":59},"2029-09-30",{"name":5,"class":6},1]